Anthracyclines - OmicsDI

Show results for

Unknown (800)
Genomics (77)
Transcriptomics (63)
Proteomics (10)
Clinical (3)
Other (3)
Genomic (2)
Metabolomics (2)

Organisms

Homo sapiens (64)
Mus musculus (15)
Alphavirus (9)
Archaea (9)
Bacteria (9)
Betaherpesvirinae (9)
Borrelia (9)
Botrytis cinerea (9)
Candida albicans (9)
Clostridium perfringens (9)
Eukaryota (9)
Fungi (9)
Hepatitis B virus (9)
Herpesvirales (9)
Human betaherpesvirus 5 (9)
Influenza A virus (9)
Influenza C virus (9)
Japanese encephalitis virus group (9)
Mammarenavirus (9)
Miscanthus x giganteus (9)
Mycobacterium tuberculosis (9)
Orthoflavivirus (9)
Panicum virgatum (9)
Rattus (9)
Saccharomyces cerevisiae (9)
Schizosaccharomyces (9)
Schizosaccharomyces pombe (9)
Saccharomyces cerevisiae (3)
Rattus norvegicus (2)
Drosophila melanogaster (1)

Organisms

Homo sapiens (43)
Mus musculus (5)
Streptomyces peucetius subsp. caesius ATCC 27952 (1)
Drosophila melanogaster (1)
Rattus norvegicus (1)

Repository

ENA (61)
geo (43)
biostudies-arrayexpress (36)
pride (9)
EGA (3)
dbGaP (2)
GNPS (1)
MassIVE (1)
MetaboLights (1)

Tissue

Cell culture (3)
Heart (3)
Permanent cell line cell (2)
Cardiac muscle cell (1)
Cell suspension culture (1)
Spleen (1)
T cell (1)

Disease

Cardiovascular system disease (2)
Patiens with confirmed metastatic breast or colorectal cancer. Breast:Pats should have received/failed at least 1 but no more than 2 lines of chemotherapy with taxanes and/or anthracyclines for me... (1)
Diarrhea (1)
Carcinoma (1)
Acute T cell leukemia (1)
Colon cancer (1)
Lymphoma (1)
Urinary bladder cancer (1)

Technology Type

Mass Spectrometry (9)
Bottom-up proteomics (4)
Data-dependent acquisition (4)
Shotgun proteomics (3)
Illumina HiSeq 2000 (1)
Mass spectrometry (1)
Data-independent acquisition (1)

Instrument Platform

Illumina NovaSeq 6000 (2)
ACQUITY RDa Detector (2)
LCMS-9030 (2)
DNBSEQ-G400 (1)
Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)

Publication Date

2025 (13)
2012 (11)
2026 (8)
2024 (8)
2013 (7)
2023 (7)
2014 (6)
2010 (4)
2009 (4)
2022 (4)
2017 (3)
2016 (3)
2015 (3)
2008 (3)
2019 (3)
2011 (2)
2021 (1)
2020 (1)

Metabolite Name

Z-ligustilide (1)
Valsartan acid (1)
Torularhodin (1)
Taxol c (1)
T-butyldimethylsilyl-corey lactone aldehyde (1)
Soyasaponin ba (1)
Soyasapogenol b base + o-hexa-pen-hex, o-hex (1)
Sibiricose a6 (1)
Schweinfurthin e (1)
Raffinose undecaacetate (1)
Rac-trans-4-cotininecarboxylic acid methyl ester (1)
Pyroglu-Gly-Arg (1)
Pyroglu-Asp (1)
Pseudoerythromycin a enol ether (1)
Prostaglandin f2.alpha. diethylamide (1)
Prostaglandin f2.alpha. 1,9-lactone (1)
Previtamin d3 (1)
Pholedrine (1)
Phenanthridin-6-ol (1)
Palmitoyl coa (1)
Palmitoyl 3-carbacyclic phosphatidic acid (1)
P-methoxymethamphetamine (1)
P-Fluorophenylalanine (1)
O-methyl-l-threonine (1)
Nga3 (1)
Ng-amino-l-arginine (1)
N1,n1,n2-trimethyl-n2-(4-piperidinyl)-1,2-ethanediamine (1)
N.alpha.-methyl-l-lysine (1)
N-trifluoroacetyl deacetylcolchiceine (1)
N-nitrosodi-n-butylamine (1)

First Public Date

2025 (15)
2024 (9)
2014 (8)
2023 (7)
2017 (6)
2022 (5)
2020 (4)
2026 (3)
2021 (1)
2019 (1)
2015 (1)
2013 (1)

Study status

Completed (2)
Terminated (1)

Study type

Transcription profiling by array (25)
RNA-seq of coding RNA (4)
ChIP-seq (2)
Interventional (2)
RNAi profiling by array (1)
Transcription profiling by RT-PCR (1)
Comparative genomic hybridization by array (1)
Other (1)
MicroRNA profiling by array (1)
Observational (1)

Release Date

2022 (99)
2025 (95)
2021 (85)
2023 (82)
2020 (65)
2024 (53)
2019 (50)
2017 (48)
2018 (41)
2016 (37)
2015 (33)
2013 (24)
2014 (22)
2012 (22)
2010 (21)
2011 (18)
2009 (14)
2026 (12)
2008 (6)
2007 (3)
2006 (2)
2005 (2)
2003 (1)
2000 (1)

Lab affiliation

Department of Pathology, Dalhousie University (2)
1 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, China. 2 Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. (1)
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid. (1)
Department of Cancer Sciences, Cleveland Clinic, 9500 Euclid Avenue, NE60, Cleveland, OH, 44195, USA. (1)
Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands (1)
Max Planck Institute for Terrestrial Microbiology Karl-von-Frisch Str. 10 35043 Marburg Germany (1)
ProGenTomics Laboratory of Pharmaceutical Biotechnology, Ghent University, Belgium (1)
The First Affiliated Hospital of Chongqing Medical University (1)

Location

Poland (1)
Israel (1)
United Kingdom (1)
Russia (1)
Czechia (1)
Austria (1)
United States (1)

Keyword

Diarrhoea diary (1)
Fosfluridine Tidoxil (1)
Randomised (1)
Metastatic breast cancer (1)
Octreotide (1)
Phase II (1)
Lapatinib (1)
Capecitabine (1)
HER2 (1)

Previous page
1 / 96
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 96
Next page

Sort by:

Relevance

Page size

Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial

PURPOSE: Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant TOP trial, in which patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to ev...

ORGANISM(S): Homo sapiens

2010-01-26 | E-GEOD-16446 | biostudies-arrayexpress

Targeting the 3D genome by anthracyclines for chemotherapeutic effects

PRJNA1154632 | ENA

Targeting the 3D genome by anthracyclines for chemotherapeutic effects

PRJNA1207420 | ENA

Epigenetic selectivity of TopoIIα redistribution and histone eviction of anthracyclines

PRJNA1003812 | ENA

Predicting Response to Anthracyclines in Ovarian Cancer.

Not available

S-EPMC8998349 | biostudies-literature

Multifactorial Approach to Predicting Resistance to Anthracyclines

ORGANISM(S): Homo sapiens

2010-01-26 | GSE16446 | GEO

Targeting the 3D genome by anthracyclines for chemotherapeutic effects

The chromatins are folded into three-dimensional (3D) structures inside cells, which coordinates the regulation of gene transcription by the non-coding regulatory elements. Aberrant chromatin 3D folding has been shown in many diseases, such as acute myeloid leukemia (AML), and may contribute to tumo...

ORGANISM(S): Homo sapiens

2025-01-06 | GSE276066 | GEO

Anthracyclines induce cardiotoxicity through a shared gene expression response signature

PRJNA1019366 | ENA

Targeting the 3D genome by anthracyclines for chemotherapeutic effects

The chromatins are folded into three-dimensional (3D) structures, and aberrant chromatin 3D folding has been shown in cancer. We performed ATAC-seq and TOP2A ChIP-seq to profile the potential effects of different anthracyclines on the chromatin. We identified that unique anthracycline variants selec...

ORGANISM(S): Homo sapiens

2025-01-14 | GSE285987 | GEO

Epigenetic selectivity of TopoIIα redistribution and histone eviction of anthracyclines

Anthracyclines act by disrupting the interface of TopoII and DNA and by evicting histones. The anthracycline-specific redistribution of TopoII and its association with histone eviction were addressed in K562 cells. Chromatin immunoprecipitation, followed by deep sequencing (ChIP-seq) against endogen...

ORGANISM(S): Homo sapiens

2023-08-11 | GSE240443 | GEO

Previous page
1 / 96
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 96
Next page

Sort by:

Relevance

Page size

960 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

Metabolite Name

First Public Date

Study status

Study type

Release Date

Lab affiliation

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets